Inhibiting HDAC6 to stabilize microtubules and enhance intracellular transport.

HDAX Therapeutics is advancing selective HDAC6 inhibitors to boost tubulin acetylation, thereby stabilizing microtubule formation, and enhancing cytoskeletal dynamics, misfolded protein clearance and intracellular transport. Their expected safety and efficacy profile will enable them to address unmet needs in neuropathies and cardiometabolic diseases.